Exagen Inc.
XGNHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframePart of the healthcare sector, Exagen Inc. (XGN) is listed under Diagnostics & Research. Valued at $176.1M, XGN is a micro-cap name in its sector. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Market Cap
$176.1M
Beta
2.12
P/E (TTM)
—
P/E (Fwd)
-15.47
EPS (TTM)
$-0.79
EPS (Fwd)
$-0.47
ROE
-113.8%
ROA
-14.9%
Cash
$24.6M
Total Debt
$27.7M
Free CF
-$1.6M
52W Change
-39.2%
Annual Financials
Cash vs Debt
Where XGN stands vs its 150-day and 200-day moving averages
As of the October 5, 2026 close, XGN finished 68.11% above its 150-day moving average ($4.86) and 69.15% above its 200-day moving average ($4.83). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is XGN overbought or oversold?
At the October 5, 2026 close, XGN's RSI(14) was 64.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $24.6M in cash, though total debt stands at $27.7M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$1.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -113.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $45.6M (2022) to $66.6M (2025), reflecting a 46% increase over the period.
A beta of 2.12 means XGN is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Exagen Inc. and its sector.